Authors
Latest:
Dr. Rule on Potential for CAR T-Cell Therapy in MCLSimon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.
Latest:
Dr. Wong on Investigational CAR T-Cell Products in Multiple MyelomaSandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.
Latest:
Dr. Ramakrishnan on Use of CAR T-Cell Therapy in MCLPraveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).
Latest:
Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple MyelomaParameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Latest:
Unmet Needs and Management in Multiple Myeloma: Peter Voorhees, MDThe hematologist/oncologist discussed unmet needs and novel therapies in multiple myeloma and give practical advice for community oncologists.
Latest:
Andrea Price, APN, Discusses Electronic Medical Records in CAR T-Cell TherapyThe associate director for clinical research at the Washington University School of Medicine spoke about the value and challenges of using EMRs in CAR T-cell therapy.
Latest:
Advantages of Off-the-Shelf CAR NK Therapy in B-Cell MalignanciesBob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.
Latest:
Dr. Gauthier on Potential for CAR T Cells in CLLJordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.
Latest:
Dr. Goy on Next Steps With CAR T-Cell Therapy in MCLAndre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALLChing-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.
Latest:
Dr. Jain on Hematopoietic Recovery Following CAR T-Cell TherapyTania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.
Latest:
Dr. Adusumilli on the Development of CAR T Cells in Solid TumorsPrasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.
Latest:
The Future of Frontline CAR T in Mantle Cell Lymphoma: Brad S. Kahl, MDThe professor of medicine at Washington University School of Medicine in St. Louis discussed the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.
Latest:
Further Research With Tab-Cel in EBV+ Post-Transplant Lymphoproliferative DiseaseAJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.
Latest:
Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-celThe assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.
Latest:
Keys to a Successful Cell and Gene Therapy LaunchThe success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.
Latest:
Adrian Kilcoyne, MD, MPH, MBA, on Adjusting Expectations for Remission Rates in Non–CAR-T Cell Therapy TrialsThe chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
Latest:
Next Steps With CAR T-Cell Therapy in Multiple Myeloma: Omar Castaneda Puglianini, MDThe hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.
Latest:
Handling Neuromuscular Gene Therapy at Real-World SitesNatalie Goedeker, CPNP, the codirector of pediatric neuromuscular clinical research at Washington University in St. Louis, discussed the session she chaired at MDA’s 2025 conference.
Latest:
Transplant Eligibility Versus CAR-T EligibilityManali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Latest:
Targeting Unmet Needs in Rare Dermatologic Diseases With Gene TherapyMatthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.
Latest:
Recognizing and Managing AEs in CAR T-Cell TherapyKelly Garvin, BSN, RN, OCN, discussed methods to communicate the benefits and risks of CAR T-cell therapy to patients and recognize AEs.
Latest:
Olivier Danos, PhD, on Enhancing Gene Therapy for DMDThe chief scientific officer at REGENXBIO discussed RGX-202 and the ongoing clinical trial.
Latest:
Evaluating Lyell’s CAR-T IMPT-314 in LBCLSarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
John Murphy, PhD, on Using Gene Editing to Tackle Primary Hyperoxaluria Type 1The chief scientific officer of Arbor Biotechnologies discussed the company’s preclinical candidate ABO-101.
Latest:
Future Plans for Evaluating Spur Therapeutics’ FLT201Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital, discussed areas of interest for future study for the Gaucher disease gene therapy product.
Latest:
A Review of Autologous Stem Cell Transplantation in AmyloidosisIuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Sharif Tabebordbar, PhD, on Improving In Vivo Gene Editing for DMDThe cofounder and chief executive officer of Kate Therapeutics discussed research that awarded him an Outstanding New Investigator at the ASGCT 2024 meeting.
